Bupropion is the only antidepressant consistently linked to weight loss rather than weight gain. In clinical studies, people taking bupropion lost between 0.22 and 3.2 kilograms, while nearly every other antidepressant on the market either holds weight steady or adds it. If you’re starting treatment for depression and weight is a concern, bupropion is the option most likely to work in your favor.
That said, “best” depends on your full picture. An antidepressant that helps you lose a few pounds but doesn’t treat your depression isn’t doing its job. Here’s what the evidence shows about how different antidepressants affect weight, why bupropion stands apart, and what other options look like.
Why Bupropion Promotes Weight Loss
Bupropion works differently from most antidepressants. Instead of targeting serotonin, it increases the activity of dopamine and norepinephrine, two brain chemicals that play central roles in appetite, satiety, and feeding behavior. The exact weight loss mechanism isn’t fully mapped out, but the dopamine and norepinephrine pathways it activates are the same ones your brain uses to regulate hunger signals and energy expenditure. In practical terms, many people on bupropion simply feel less hungry.
Compared to sertraline (Zoloft), a commonly prescribed baseline antidepressant, bupropion users lost about 0.22 kg more over six months. That’s modest on its own, but the gap widens when you compare bupropion to antidepressants that cause significant gain. Someone choosing bupropion over mirtazapine, for example, could see a net difference of nearly 5 kg over the same period. Bupropion also carries a 15% reduced risk of gaining 5% or more of your body weight, which is the threshold doctors consider clinically meaningful.
How Other Antidepressants Compare
Most antidepressants cause at least some weight gain. The amount varies widely by class and specific drug.
Among SSRIs, paroxetine (Paxil) is the worst offender, adding 0.37 to 2.73 kg on average, with a 21% higher chance of clinically significant weight gain. It has strong antihistamine-like effects that stimulate appetite. Escitalopram (Lexapro) is milder but still trends upward, averaging about 0.41 kg over six months. Fluoxetine (Prozac) is the notable exception in this class: it’s essentially weight-neutral over time. People typically lose a small amount in the first few weeks (around 0.4 kg), but that loss doesn’t stick. A year-long controlled trial found that after depression symptoms improved, weight gain on fluoxetine was no different from placebo. The early loss appears tied to appetite suppression that fades, not a lasting metabolic effect.
SNRIs fall in the middle. Venlafaxine (Effexor) adds a modest 0.17 kg on average, while duloxetine (Cymbalta) comes in at about 0.34 kg. Neither is dramatic, but neither helps with weight loss.
The biggest weight gainers are older tricyclic antidepressants like amitriptyline and nortriptyline (1.5 to 2 kg in short-term use), mirtazapine (1.74 kg), and the MAOI phenelzine (2 to 3 kg over six months). Mirtazapine is particularly notable because it blocks histamine and serotonin receptors in ways that directly increase appetite. Tricyclics as a class also tend to cause more metabolic disruption, including changes to blood sugar and cholesterol levels, than SSRIs do.
Weight-Neutral Alternatives Worth Knowing
If bupropion isn’t a good fit for you, a few antidepressants sit close to zero on the weight scale. Fluoxetine, as mentioned, is essentially neutral long-term. Vortioxetine (Trintellix), a newer option, showed no significant weight changes in short-term clinical trials, and only 0.67 kg of gain in one long-term study. It does come with higher rates of nausea, which some people find hard to tolerate. Venlafaxine’s gain is small enough that many clinicians consider it nearly weight-neutral as well.
These won’t help you lose weight, but they’re reasonable choices if your priority is treating depression without adding pounds.
Bupropion Plus Naltrexone for Greater Weight Loss
For people who need more significant weight management, bupropion is also available in a combination tablet with naltrexone, sold as Contrave. This is FDA-approved specifically for weight loss in adults with obesity or overweight with at least one weight-related health condition. It pairs bupropion’s appetite-suppressing effects with naltrexone, which reduces food cravings through a different pathway.
The results are meaningful. In a 56-week trial, people on the combination lost an average of 5.4% of their body weight, compared to 1.3% on placebo. When paired with intensive lifestyle changes like diet counseling and exercise, that number climbed to 8.1%. About 42% of people on the medication hit the 5% weight loss mark, and that percentage rose to 57% with structured lifestyle support. For people with type 2 diabetes, outcomes were more modest at 3.7% body weight lost, roughly double the placebo group.
The FDA recommends checking progress after 12 weeks at full dose. If you haven’t lost at least 5% of your starting weight by then, the medication is unlikely to produce meaningful results and is typically discontinued.
Who Should Avoid Bupropion
Bupropion lowers the seizure threshold, which makes it unsafe for certain people. It is contraindicated if you have a current or past eating disorder, including anorexia nervosa and bulimia nervosa. The seizure risk is elevated in people whose bodies are already under metabolic stress from disordered eating, low weight, or purging behaviors that disrupt electrolyte balance.
It’s also not appropriate for people with seizure disorders, those withdrawing from alcohol or sedatives, or anyone taking other medications that lower the seizure threshold. If any of these apply, a weight-neutral option like fluoxetine or vortioxetine is a safer starting point for depression treatment.
Beyond the Scale: Metabolic Effects
Weight is only one piece of the metabolic picture. Some antidepressants affect blood sugar and cholesterol independently of weight changes. Mirtazapine, for instance, has been shown to alter glucose and lipid levels even in people who don’t gain weight on it. Tricyclics as a class carry higher rates of inflammatory and metabolic changes compared to SSRIs. And antidepressant use in general has been linked to lower HDL (“good”) cholesterol and higher blood sugar in some studies, though the relationship between depression itself and these markers makes it hard to separate cause from treatment effect.
Bupropion doesn’t carry these same metabolic red flags. Its mechanism of action avoids the histamine and serotonin receptor activity most associated with metabolic disruption, which is part of why it’s the go-to when weight and metabolic health are priorities alongside mood.